|Bid||49.72 x 900|
|Ask||49.73 x 900|
|Day's Range||49.14 - 49.89|
|52 Week Range||41.32 - 58.00|
|Beta (5Y Monthly)||0.30|
|PE Ratio (TTM)||22.87|
|Earnings Date||Nov 01, 2022 - Nov 07, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||53.38|
Subscribe to Yahoo Finance Plus to view Fair Value for QGEN
How far off is Qiagen N.V. ( NYSE:QGEN ) from its intrinsic value? Using the most recent financial data, we'll take a...
QIAGEN (QGEN) posts better-than-expected results for the second quarter and raises its sales and earnings outlook for 2022 amid the uncertain macroeconomic environment.
Qiagen N.V. (NYSE: QGEN) clocked Q2 FY22 revenues of $516 million, down 9% Y/Y, well above the consensus of $488.73 million. At constant exchange rates (CER), Qiagen's Q2 sales fell 4 percent to $544 million, besting previous company guidance of $510 million at CER. Qiagen's non-COVID product groups, now comprising more than 80% of its sales, rose 4% (10% at CER) to $423 million, tempered by an expected decline of 42% (39% at CER) in its COVID-19 products to $92 million. Adjusted EPS reached $0.